Leptin-based adjuvants: An innovative approach to improve vaccine response

Sarah J. White, Matthew J. Taylor, Ryan T Hurt, Michael Dennis Jensen, Gregory A. Poland

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Leptin is a pleiotropic hormone with multiple direct and regulatory immune functions. Leptin deficiency or resistance hinders the immunologic, metabolic, and neuroendocrinologic processes necessary to thwart infections and their associated complications, and to possibly protect against infectious diseases following vaccination. Circulating leptin levels are proportional to body fat mass. High circulating leptin concentrations, as observed in obesity, are indicative of the development of leptin transport saturation/signaling desensitization. Leptin bridges nutritional status and immunity. Although its role in vaccine response is currently unknown, over-nutrition has been shown to suppress vaccine-induced immune responses. For instance, obesity (BMI≥30kg/m2) is associated with lower antigen-specific antibody titers following influenza, hepatitis B, and tetanus vaccinations. This suggests that obesity, and possibly saturable leptin levels, are contributing factors to poor vaccine immunogenicity. While leptin-based therapies have not been investigated as vaccine adjuvants thus far, leptin's role in immunity suggests that application of these therapies is promising and worth investigation to enhance vaccine response in people with leptin signaling impairments. This review will examine the possibility of using leptin as a vaccine adjuvant by: briefly reviewing the distribution and signal transduction of leptin and its receptors; discussing the physiology of leptin with emphasis on its immune functions; reviewing the causes of attenuation of leptin signaling; and finally, providing plausible inferences for the innovative use of leptin-based pharmacotherapies as vaccine adjuvants.

Original languageEnglish (US)
Pages (from-to)1666-1672
Number of pages7
JournalVaccine
Volume31
Issue number13
DOIs
StatePublished - Mar 25 2013

Fingerprint

Leptin
leptin
adjuvants
Vaccines
vaccines
vaccine adjuvants
Obesity
obesity
Immunity
Vaccination
immunity
vaccination
immune response
Leptin Receptors
therapeutics
Tetanus
tetanus
hepatitis B
Nutritional Status
Hepatitis B

Keywords

  • Adipokine
  • Adjuvant
  • Infectious diseases
  • Leptin
  • Obesity
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Leptin-based adjuvants : An innovative approach to improve vaccine response. / White, Sarah J.; Taylor, Matthew J.; Hurt, Ryan T; Jensen, Michael Dennis; Poland, Gregory A.

In: Vaccine, Vol. 31, No. 13, 25.03.2013, p. 1666-1672.

Research output: Contribution to journalArticle

White, Sarah J. ; Taylor, Matthew J. ; Hurt, Ryan T ; Jensen, Michael Dennis ; Poland, Gregory A. / Leptin-based adjuvants : An innovative approach to improve vaccine response. In: Vaccine. 2013 ; Vol. 31, No. 13. pp. 1666-1672.
@article{3c1a817a14334004b8e3f8ccfa83247e,
title = "Leptin-based adjuvants: An innovative approach to improve vaccine response",
abstract = "Leptin is a pleiotropic hormone with multiple direct and regulatory immune functions. Leptin deficiency or resistance hinders the immunologic, metabolic, and neuroendocrinologic processes necessary to thwart infections and their associated complications, and to possibly protect against infectious diseases following vaccination. Circulating leptin levels are proportional to body fat mass. High circulating leptin concentrations, as observed in obesity, are indicative of the development of leptin transport saturation/signaling desensitization. Leptin bridges nutritional status and immunity. Although its role in vaccine response is currently unknown, over-nutrition has been shown to suppress vaccine-induced immune responses. For instance, obesity (BMI≥30kg/m2) is associated with lower antigen-specific antibody titers following influenza, hepatitis B, and tetanus vaccinations. This suggests that obesity, and possibly saturable leptin levels, are contributing factors to poor vaccine immunogenicity. While leptin-based therapies have not been investigated as vaccine adjuvants thus far, leptin's role in immunity suggests that application of these therapies is promising and worth investigation to enhance vaccine response in people with leptin signaling impairments. This review will examine the possibility of using leptin as a vaccine adjuvant by: briefly reviewing the distribution and signal transduction of leptin and its receptors; discussing the physiology of leptin with emphasis on its immune functions; reviewing the causes of attenuation of leptin signaling; and finally, providing plausible inferences for the innovative use of leptin-based pharmacotherapies as vaccine adjuvants.",
keywords = "Adipokine, Adjuvant, Infectious diseases, Leptin, Obesity, Vaccine",
author = "White, {Sarah J.} and Taylor, {Matthew J.} and Hurt, {Ryan T} and Jensen, {Michael Dennis} and Poland, {Gregory A.}",
year = "2013",
month = "3",
day = "25",
doi = "10.1016/j.vaccine.2013.01.032",
language = "English (US)",
volume = "31",
pages = "1666--1672",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "13",

}

TY - JOUR

T1 - Leptin-based adjuvants

T2 - An innovative approach to improve vaccine response

AU - White, Sarah J.

AU - Taylor, Matthew J.

AU - Hurt, Ryan T

AU - Jensen, Michael Dennis

AU - Poland, Gregory A.

PY - 2013/3/25

Y1 - 2013/3/25

N2 - Leptin is a pleiotropic hormone with multiple direct and regulatory immune functions. Leptin deficiency or resistance hinders the immunologic, metabolic, and neuroendocrinologic processes necessary to thwart infections and their associated complications, and to possibly protect against infectious diseases following vaccination. Circulating leptin levels are proportional to body fat mass. High circulating leptin concentrations, as observed in obesity, are indicative of the development of leptin transport saturation/signaling desensitization. Leptin bridges nutritional status and immunity. Although its role in vaccine response is currently unknown, over-nutrition has been shown to suppress vaccine-induced immune responses. For instance, obesity (BMI≥30kg/m2) is associated with lower antigen-specific antibody titers following influenza, hepatitis B, and tetanus vaccinations. This suggests that obesity, and possibly saturable leptin levels, are contributing factors to poor vaccine immunogenicity. While leptin-based therapies have not been investigated as vaccine adjuvants thus far, leptin's role in immunity suggests that application of these therapies is promising and worth investigation to enhance vaccine response in people with leptin signaling impairments. This review will examine the possibility of using leptin as a vaccine adjuvant by: briefly reviewing the distribution and signal transduction of leptin and its receptors; discussing the physiology of leptin with emphasis on its immune functions; reviewing the causes of attenuation of leptin signaling; and finally, providing plausible inferences for the innovative use of leptin-based pharmacotherapies as vaccine adjuvants.

AB - Leptin is a pleiotropic hormone with multiple direct and regulatory immune functions. Leptin deficiency or resistance hinders the immunologic, metabolic, and neuroendocrinologic processes necessary to thwart infections and their associated complications, and to possibly protect against infectious diseases following vaccination. Circulating leptin levels are proportional to body fat mass. High circulating leptin concentrations, as observed in obesity, are indicative of the development of leptin transport saturation/signaling desensitization. Leptin bridges nutritional status and immunity. Although its role in vaccine response is currently unknown, over-nutrition has been shown to suppress vaccine-induced immune responses. For instance, obesity (BMI≥30kg/m2) is associated with lower antigen-specific antibody titers following influenza, hepatitis B, and tetanus vaccinations. This suggests that obesity, and possibly saturable leptin levels, are contributing factors to poor vaccine immunogenicity. While leptin-based therapies have not been investigated as vaccine adjuvants thus far, leptin's role in immunity suggests that application of these therapies is promising and worth investigation to enhance vaccine response in people with leptin signaling impairments. This review will examine the possibility of using leptin as a vaccine adjuvant by: briefly reviewing the distribution and signal transduction of leptin and its receptors; discussing the physiology of leptin with emphasis on its immune functions; reviewing the causes of attenuation of leptin signaling; and finally, providing plausible inferences for the innovative use of leptin-based pharmacotherapies as vaccine adjuvants.

KW - Adipokine

KW - Adjuvant

KW - Infectious diseases

KW - Leptin

KW - Obesity

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84875264361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875264361&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.01.032

DO - 10.1016/j.vaccine.2013.01.032

M3 - Article

C2 - 23370154

AN - SCOPUS:84875264361

VL - 31

SP - 1666

EP - 1672

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 13

ER -